Regeneron secures $1B upfront in expanded Sanofi collaboration for new antibody development.

{
  "signal_id": "295ccdb5-027b-4ae5-aef1-517be2cdfaf9",
  "signal_type": "sec-8k",
  "signal_subtype": "materialContract",
  "detected_at": "2026-10-13T07:05:30.135+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "Regeneron is expanding its partnership with Sanofi to co-develop and co-commercialize four new antibodies, with potential for an additional $7B in milestones. This major R&D and commercialization initiative provides significant immediate capital for investment in clinical development, manufacturing, and go-to-market infrastructure.",
    "metrics": {
      "timeframe": "immediate",
      "dollar_context": "Upfront payment from Sanofi for co-development and co-commercialization of four new antibodies.",
      "dollar_millions": 1000
    },
    "summary": "Regeneron secures $1B upfront in expanded Sanofi collaboration for new antibody development.",
    "excerpts": "On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi, a société anonyme organized under the laws of France (“Sanofi Parent” and, with Sanofi Biotechnology, “Sanofi”), entered into the Sixth Amendment to the Amended and Restated License and Collaboration Agreement (the “Sixth Amendment”)...",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm",
    "filing_date": "2026-10-06",
    "filing_year": 2026,
    "sales_relevance": "Vendor relationship signal",
    "signal_category": "strategic",
    "regions_mentioned": [
      "United States"
    ],
    "vendors_mentioned": [
      "Sanofi"
    ],
    "technologies_mentioned": [
      "antibodies",
      "bispecific antibody",
      "Nanobody VHH therapy"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/295ccdb5-027b-4ae5-aef1-517be2cdfaf9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'